Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05046132 · ClinicalTrials.gov registry record · Phase 4
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
A Phase 4 study of Healthy, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT05046132 is a Phase 4 study of Healthy that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 77 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05046132, a Phase 4 study of Healthy, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a double-blind, randomized, placebo- and positive-controlled, parallel group, 3-arm study that assessed the potential for therapeutic and supratherapeutic concentrations of setmelanotide to affect the QTc corrected by the Fredericia method (QTcF) interval.
Conditions Studied
Interventions
- DRUG Oral Placebo
- DRUG Moxifloxacin
- DRUG Setmelanotide
- DRUG SC Placebo
Study Locations (1)
California
- Parexel Early Phase Clinical Unit (Los Angeles) - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2021-08-05 |
| Est. Completion | 2022-04-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05046132
The ClinicalTrials.gov registry entry for NCT05046132 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (88% lower). The listed sponsor is Rhythm Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Oral Placebo is the first listed.
NCT05046132 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05046132 about?
NCT05046132 is a clinical study titled "Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants". This was a double-blind, randomized, placebo- and positive-controlled, parallel group, 3-arm study that assessed the potential for therapeutic and supratherapeutic concentrations of setmelanotide to affect the QTc corrected by the Fredericia method (QTcF) interval.
What is the current status of trial NCT05046132?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2021-08-05. Estimated completion is 2022-04-07.
What conditions does trial NCT05046132 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05046132?
The interventions under investigation include: Oral Placebo (DRUG), Moxifloxacin (DRUG), Setmelanotide (DRUG), SC Placebo (DRUG).
Who is sponsoring clinical trial NCT05046132?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05046132 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.